Clinical Trial Search

Primary: Percentage of Subjects With Confirmed Keloid Formation at Treated vs. Untreated Lesions at 24 Weeks — 92.9; 85.7 percentage of participants

Primary: Number of Participants Enrolled — 45 Participants

Primary: Primary Safety Outcome: Percentage of Participants With Procedure Related Adverse Events OR Device Related Adverse Events OR Serious Adverse Device Effects — 50…

Primary: Mean AUC (Area Under the Curve) Plasma [Glucose] — 1677; 1797; 1662 AU

Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants

Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects

Primary: Percentage of Intrinsic Ventricular Events — 82.7; 22.8 % of intrinsic ventricular events — p=<0.0001

Primary: Subjects With Treatment-Emergent Adverse Events (TEAEs) — 143; 108; 6; 2 Participants

Primary: Golimumab Induced Shifts in the Abundance of Bacterial Markers — 14965109899; 132857054401767; 12779328208; 12851286145 16S gene copies per gram of faeces

Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants

Primary: Tinnitus Functional Index (TFI); Measure of Tinnitus Distress — 61.06; 41.78; 40.38 score on a scale

Primary: Cumulative NDMA Amount Excreted in Urine Over 24 Hours After Drug Administration (Comparison Between Ranitidine and Placebo) — 0.6; 10.5; 11.9; 23.4 nanograms — p=0.54

Primary: Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) Score at Week 12 Visit Compared to Baseline — -0.05; -2.25 score on a scale

Primary: Number of Participants With a Diagnosis of a Cognitive Impairment Disorder Measured by Pharmacological Interventions for the Management of Cognitive Impairment. — 0; 0…

Primary: Medication Adherence at Baseline and 6-month Follow-up Period — 59.4; 55.95 units on a scale